Patients diagnosed with active inflammatory bowel disease demonstrate a greatly increased TRPV1 immunoreactivity in colonic nerve fibers [197, 201], suggesting an important implication of the TRPV1 antagonists in treating GI distress. This evidence concerns the gene TRPV1 and inflammatory bowel disease.